438 related articles for article (PubMed ID: 32374043)
1. Differential activity and selectivity of N-terminal modified CXCL12 chemokines at the CXCR4 and ACKR3 receptors.
Jaracz-Ros A; Bernadat G; Cutolo P; Gallego C; Gustavsson M; Cecon E; Baleux F; Kufareva I; Handel TM; Bachelerie F; Levoye A
J Leukoc Biol; 2020 Jun; 107(6):1123-1135. PubMed ID: 32374043
[TBL] [Abstract][Full Text] [Related]
2. Kinetics of CXCL12 binding to atypical chemokine receptor 3 reveal a role for the receptor N terminus in chemokine binding.
Gustavsson M; Dyer DP; Zhao C; Handel TM
Sci Signal; 2019 Sep; 12(598):. PubMed ID: 31506383
[TBL] [Abstract][Full Text] [Related]
3. Dual targeting of the chemokine receptors CXCR4 and ACKR3 with novel engineered chemokines.
Hanes MS; Salanga CL; Chowdry AB; Comerford I; McColl SR; Kufareva I; Handel TM
J Biol Chem; 2015 Sep; 290(37):22385-97. PubMed ID: 26216880
[TBL] [Abstract][Full Text] [Related]
4. Mutational Analysis of Atypical Chemokine Receptor 3 (ACKR3/CXCR7) Interaction with Its Chemokine Ligands CXCL11 and CXCL12.
Benredjem B; Girard M; Rhainds D; St-Onge G; Heveker N
J Biol Chem; 2017 Jan; 292(1):31-42. PubMed ID: 27875312
[TBL] [Abstract][Full Text] [Related]
5. The chemokine X-factor: Structure-function analysis of the CXC motif at CXCR4 and ACKR3.
Wedemeyer MJ; Mahn SA; Getschman AE; Crawford KS; Peterson FC; Marchese A; McCorvy JD; Volkman BF
J Biol Chem; 2020 Oct; 295(40):13927-13939. PubMed ID: 32788219
[TBL] [Abstract][Full Text] [Related]
6. The peptidomimetic CXCR4 antagonist TC14012 recruits beta-arrestin to CXCR7: roles of receptor domains.
Gravel S; Malouf C; Boulais PE; Berchiche YA; Oishi S; Fujii N; Leduc R; Sinnett D; Heveker N
J Biol Chem; 2010 Dec; 285(49):37939-43. PubMed ID: 20956518
[TBL] [Abstract][Full Text] [Related]
7. Different contributions of chemokine N-terminal features attest to a different ligand binding mode and a bias towards activation of ACKR3/CXCR7 compared with CXCR4 and CXCR3.
Szpakowska M; Nevins AM; Meyrath M; Rhainds D; D'huys T; Guité-Vinet F; Dupuis N; Gauthier PA; Counson M; Kleist A; St-Onge G; Hanson J; Schols D; Volkman BF; Heveker N; Chevigné A
Br J Pharmacol; 2018 May; 175(9):1419-1438. PubMed ID: 29272550
[TBL] [Abstract][Full Text] [Related]
8. Partial agonist activity of α1-adrenergic receptor antagonists for chemokine (C-X-C motif) receptor 4 and atypical chemokine receptor 3.
Gao X; Abdelkarim H; Albee LJ; Volkman BF; Gaponenko V; Majetschak M
PLoS One; 2018; 13(9):e0204041. PubMed ID: 30248140
[TBL] [Abstract][Full Text] [Related]
9. Ligand-specific conformational transitions and intracellular transport are required for atypical chemokine receptor 3-mediated chemokine scavenging.
Montpas N; St-Onge G; Nama N; Rhainds D; Benredjem B; Girard M; Hickson G; Pons V; Heveker N
J Biol Chem; 2018 Jan; 293(3):893-905. PubMed ID: 29180449
[TBL] [Abstract][Full Text] [Related]
10. ACKR3 Regulation of Neuronal Migration Requires ACKR3 Phosphorylation, but Not β-Arrestin.
Saaber F; Schütz D; Miess E; Abe P; Desikan S; Ashok Kumar P; Balk S; Huang K; Beaulieu JM; Schulz S; Stumm R
Cell Rep; 2019 Feb; 26(6):1473-1488.e9. PubMed ID: 30726732
[TBL] [Abstract][Full Text] [Related]
11. Common structural interactions between the receptors CXCR3, CXCR4 and CXCR7 complexed with their natural ligands, CXCL11 and CXCL12, by a modeling approach.
Costantini S; Raucci R; De Vero T; Castello G; Colonna G
Cytokine; 2013 Oct; 64(1):316-21. PubMed ID: 23773308
[TBL] [Abstract][Full Text] [Related]
12. Atypical Chemokine Receptor 3 "Senses" CXC Chemokine Receptor 4 Activation Through GPCR Kinase Phosphorylation.
Schafer CT; Chen Q; Tesmer JJG; Handel TM
Mol Pharmacol; 2023 Oct; 104(4):174-186. PubMed ID: 37474305
[TBL] [Abstract][Full Text] [Related]
13. Characterization of a chimeric chemokine as a specific ligand for ACKR3.
Ameti R; Melgrati S; Radice E; Cameroni E; Hub E; Thelen S; Rot A; Thelen M
J Leukoc Biol; 2018 Aug; 104(2):391-400. PubMed ID: 29601107
[TBL] [Abstract][Full Text] [Related]
14. Development of novel CXC chemokine receptor 7 (CXCR7) ligands: selectivity switch from CXCR4 antagonists with a cyclic pentapeptide scaffold.
Oishi S; Kuroyanagi T; Kubo T; Montpas N; Yoshikawa Y; Misu R; Kobayashi Y; Ohno H; Heveker N; Furuya T; Fujii N
J Med Chem; 2015 Jul; 58(13):5218-25. PubMed ID: 26042340
[TBL] [Abstract][Full Text] [Related]
15. α
Albee LJ; Eby JM; Tripathi A; LaPorte HM; Gao X; Volkman BF; Gaponenko V; Majetschak M
J Am Heart Assoc; 2017 Aug; 6(8):. PubMed ID: 28862946
[TBL] [Abstract][Full Text] [Related]
16. Imaging ligand-dependent activation of CXCR7.
Luker KE; Gupta M; Steele JM; Foerster BR; Luker GD
Neoplasia; 2009 Oct; 11(10):1022-35. PubMed ID: 19794961
[TBL] [Abstract][Full Text] [Related]
17. Structural basis of ligand interaction with atypical chemokine receptor 3.
Gustavsson M; Wang L; van Gils N; Stephens BS; Zhang P; Schall TJ; Yang S; Abagyan R; Chance MR; Kufareva I; Handel TM
Nat Commun; 2017 Jan; 8():14135. PubMed ID: 28098154
[TBL] [Abstract][Full Text] [Related]
18. Mutational analysis of the extracellular disulphide bridges of the atypical chemokine receptor ACKR3/CXCR7 uncovers multiple binding and activation modes for its chemokine and endogenous non-chemokine agonists.
Szpakowska M; Meyrath M; Reynders N; Counson M; Hanson J; Steyaert J; Chevigné A
Biochem Pharmacol; 2018 Jul; 153():299-309. PubMed ID: 29530506
[TBL] [Abstract][Full Text] [Related]
19. Breast Cancer: An Examination of the Potential of ACKR3 to Modify the Response of CXCR4 to CXCL12.
Del Molino Del Barrio I; Wilkins GC; Meeson A; Ali S; Kirby JA
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30441765
[TBL] [Abstract][Full Text] [Related]
20. Effects of Small Molecule Ligands on ACKR3 Receptors.
Hopkins BE; Masuho I; Ren D; Iyamu ID; Lv W; Malik N; Martemyanov KA; Schiltz GE; Miller RJ
Mol Pharmacol; 2022 Sep; 102(3):128-138. PubMed ID: 35809897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
